Drugs / MPL-Adjuvanted Recombinant Hepatitis B Vaccine
MPL-Adjuvanted Recombinant Hepatitis B Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00697931 | May 1997 → Jun 1998 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00698087 | Jan 1995 → Feb 1996 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MPL-Adjuvanted Recombinant Hepatitis B Vaccine | “Study to Compare the Immunogenicity and Reactogenicity of GSK Biologicals; (Previously SmithKline Beecham Biologicals') MPL-Adjuvanted Recombinant Hepatitis B Vaccine With That...” NCT00697931 ↗ |
| Modality | Vaccine | “adjuvanted recombinant hepatitis B vaccine” NCT00697931 ↗ |
| Route | Intramuscular | “Intramuscular injection” NCT00697931 ↗ |